BPGbio, Inc.

👏 BPGbio, Inc.'s leading clinical candidate, BPM31510, is rapidly becoming a potential franchise drug! 👏 Developed using the BPGbio, Inc. NAi Interrogative Biology platform BPM31510 is being tested in topical, intravenous, and oral formulations; BPM31510T, BPM31510IV and BPM31510 Oral, respectively.  “While conditions like #EB, CoQ10 deficiency, and #cancer, may seem unrelated, they share mitochondrial dysfunction as a root cause. BPGbio, Inc. is committed to further developing BPM31510 in the mitochondria medicine space through strategic #partnerships to bring the benefits of #therapeutics to underserved patients," as stated by Niven R Narain, Ph.D., President & CEO, BPGbio, Inc. - BPM31510T has received #FDA Rare Pediatric Disease designation for #EB and completed a phase 1 trial for #EB and a phase 2 trial for #SCC; - BPM31510IV is being studied in ongoing phase 2B trial for glioblastoma multiforme (orphan drug) and has completed a phase 2A trial for pancreatic cancer (orphan drug); - BPM31510IV has recently received #FDA Rare Pediatric Disease designation for its potential treatment for primary coenzyme Q10 deficiency. The company is planning a potential pivotal trial of BPM31510IV targeting multiple CoQ10 deficiency mutations at multiple U.S. and EU sites; - BPM31510 Oral A phase 2 trial for #Sarcopenia is currently being planned for BPM31510 Oral. 👉 For more information, please visit www.bpgbio.com #AI #NAiInterrogativeBiology #mitochondrialdysfunction #mitochondriamedicine #primarycoq10deficiency #drugdiscovery #drugdevelopment #pancreaticcancer #gbm #clinicaltrials

🎗 Please join BPGbio, Inc. in supporting #research, #therapeutics and #diagnostics, as well as #support communities, for #pancreaticcancer this November #PancreaticCancerAwarenessMonth 🎗 Pancreatic cancer is a disease with a high unmet medical need. In the United States, over 65,000 adults are diagnosed with pancreatic cancer every year. Over 50,000 will die from it. The majority of pancreatic cancer cases are diagnosed late, at which point the disease is already locally advanced or metastatic. The disease accounts for about 3 percent of all cancers in the US and is the third leading cause of #cancer death in men and women (~7%) according to the American Cancer Society. At BPGbio, Inc. we have been developing therapeutics and diagnostics targeting pancreatic cancer for many years. Our pancreatic cancer drug candidate (BPM31510) received #FDA Orphan-Drug Designation in November, 2017, and has completed a phase 2 #clinicaltrial. Project Survival is a precision health #biomarker discovery program for pancreatic cancer patients utilizing the BPGbio, Inc. NAi Interrogative Biology platform. With 452 participants longitudinally molecularly characterized and clinical phenotyped, Project Survival represents the most comprehensive precision health assessment existing for pancreatic cancer. The objective of Project Survival is to transform novel predictive diagnostics and tailored therapies for patients with pancreatic cancer. BPGbio, Inc. is currently exploring commercial opportunities globally for this technology branded pancDx™. The test is currently not commercially available in the United States. ➡ If you'd like to help support efforts and communities with pancreatic cancer, please visit the World Pancreatic Cancer Coalition website where you can find communities and programs in your region. https://lnkd.in/eCJMerQ ➡ For more information on BPGbio, Inc.'s pancreatic cancer candidate BPM31510, please visit: https://lnkd.in/g4vGGtZt ➡ For more information on BPGbio, Inc.'s pancreatic cancer diagnostic panel, pancDx™, and Project Survival, please visit: https://lnkd.in/g56cxVRb #projectsurvival #worldpancreaticcancercoalition #NAiInterrogativeBiology #ItsAboutTime #WPCD #PanCAN #PanCANawareness #NPCF #Hope4PC

🎙 BPGbio, Inc.'s President & CEO, Niven R. Narain, Ph.D., presented at the inaugural Google Cancer AI Symposium October 30. Dr. Narain's presentation titled “Making AI for Discovery Real - Prioritizing Biology before Tech,” showcased our biology-first approach and the following: - BPGbio, Inc.'s robust portfolio of therapeutic candidates including those currently in #clinicaltrials including a therapeutic #pipeline that includes candidates for #glioblastoma (orphan drug), #pancreaticcancer (orphan drug), #primaryCoQ10deficiency (rare pediatric disease designation), #epidermolysisbullosa (orphan drug, rare pediatric disease designation), squamous cell carcinoma (orphan drug), #sarcopenia, solid and liquid tumors, #Huntington’s disease, and #Parkinson’s disease. - The NAi Interrogative Biology platform and it's role in target discovery, #biomarker identification, and #drugdevelopment. Also, he discussed how the NAi platform is advancing #partnerships across industries. BPGbio, Inc., a leading biology-first, AI-powered, clinical stage hashtag #biopharma focused on mitochondrial biology and protein homeostasis. For more information about BPGbio, Inc. please visit our website at www.bpgbio.com Further information on our NAi Interrogative Biology platform and partnership opportunies can be found at https://lnkd.in/gvTXPEEf #AI #GoogleAI #cancer #presentations #biology #drugdiscovery #GoogleCancerAISymposium #NAiInterrogativeBiology

🎃 Halloween fright has overcome the BPGbio, Inc. offices! 🎃 Thank you to all the employees who came and showed their Halloween spirit (pun?) this year! As viewers at home will notice, it was just simply SCARY! 😱 All kidding aside, we appreciate all the hard work our team does in our mission to find treatments and cures. Our team is second to none! Happy Halloween everyone! 👻 #halloween #companyculture #costumes #horror

📢 BPGbio, Inc. Receives FDA Rare Pediatric Disease Designation for its Investigational Treatment for Epidermolysis Bullosa ●    This marks the company’s second Rare Pediatric Disease Designation for BPM31510 franchise in the last two months ●    BPM31510T targets mitochondrial machinery to promote wound healing in EB patients BPGbio, Inc., a leading biology-first, AI-powered, clinical stage #biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food and Drug Administration (#FDA) has granted a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for #epidermolysisbullosa (#EB). This designation coincides with #EBAwarenessWeek, observed annually from October 25-31, highlighting the urgent need for innovative EB treatments. The FDA’s Rare Pediatric Disease Designation is intended for companies developing treatments for pediatric diseases that currently lack approved therapies. This designation provides BPGbio, Inc. eligibility for a priority review voucher upon BPM31510T’s approval for EB. It is the second Rare Pediatric Disease Designation that BPGbio, Inc. has received for BPM31510, with the initial designation awarded last month for #primaryCoQ10deficiency. BPM31510T has also received the FDA’s Orphan Drug Designation. BPM31510 is BPGbio, Inc.’s leading clinical candidate in topical, intravenous, and oral formulations. ●    BPM31510T has completed a phase 1 trial for EB and phase 2 for SCC; ●    BPM31510IV is being studied in ongoing Phase 2B for glioblastoma multiforme (orphan drug) and has completed a Phase 2A for pancreatic cancer (orphan drug); ●    BPM31510IV has recently received FDA Rare Pediatric Disease designation for its potential treatment for primary coenzyme Q10 deficiency. The company is planning a potential pivotal trial of BPM31510IV targeting multiple CoQ10 deficiency mutations at multiple U.S. and EU sites; ●    BPM31510 Oral A Phase 2 trial for Sarcopenia is currently being planned for BPM 31510 Oral ➡ Full release: https://lnkd.in/giu_whND #AI #orphandrugs #drugdevelopment #therapeutics #epidermolysisbullosa #NAiInterrogativeBiology #raredisease #debraofamerica #pediatricdisease

⚕ Niven R Narain, Ph.D. has written a new article for Today's Clinical Lab: "Prostate Clarity: A New Noninvasive Biomarker for Prostate Cancer Screening" In the piece, Dr. Narain discusses how BPGbio, Inc.'s NAi Interrogative Biology platform discovered the novel protein-based biomarker used in our #pstateDx test which has been shown through our studies and subsequent #clinicaltrials to use filamin A levels in serum to differentiate between benign prostatic hyperplasia (#BPH) and #prostatecancer. This is a profound differentiation that can greatly reduce false positives for prostate cancer often found in standard PSA testing. A key point from the article: "Filamin A is the first-ever AI-discovered protein-based oncology biomarker, and it underscores the potential of AI-powered platforms in the discovery and development of diagnostic tools." ➡ Full story on Today's Clinical Lab can be found here: https://lnkd.in/guT6AFur Please check it out and support Today's Clinical Lab. ➡ For more information about BPGbio, Inc.'s pstateDx test, please visit: https://lnkd.in/gGeteQmZ #cancerdetection #artificialintelligence #cancerscreening #biomarkers #NAiInterrogativeBiology #biopharma #research #drugdiscovery #diagnostics

📣 Michael Kiebish, Ph.D., of BPGbio, Inc. presents new data on BPM31510 and novel #quinomics technology for treatment of primary CoQ10 deficiency at #MitoCon2024 The poster presentation titled "Employment of Spatial Omics and Quinomics Technologies for the Advancement of Mitochondrial Targeted Therapeutics" was presented October 25th in Padova, Italy. Showcasing the #collaboration between BPGbio, Inc. and Columbia University, the presentation detailed how quinomics is being used to precisely assess the bioanalytical and spatial measurements of therapeutic effects of BPM31510, BPGbio, Inc.'s potentially revolutionary treatment for #mitochondrialdisease such as #primaryCoQ10deficiency. Dr. Kiebish also discussed the considerably improved performance of BPM31510 over traditional oral CoQ10 in treating #mitochondrialdysfunction. ➡ We are currently planning a potential pivotal trial for primary CoQ10 deficiency. ➡ BPGbio, Inc. received #FDA Rare Pediatric Disease Designation for its Potential Treatment for Primary Coenzyme Q10 Deficiency. Additionally, BPM31510 demonstrated a tolerable safety profile in clinical trials and is currently being studied as an #oncology drug candidate for two disease indications: #glioblastoma and #pancreaticcancer ➡ For more information about BPGbio, Inc.'s primary CoQ10 disease program, please visit: https://lnkd.in/gmAvyU-W ➡ The full presentation poster can be downloaded here: https://lnkd.in/gmh8isFG #mitochondrialbiology #AI #proteinhomeostasis #spatialomics #NAiInterrogativeBiology #MitoCon2024 #Italy #columbiauniversity #therapeutics #raredisease #biopharma #research

👀 Vivek K Vishnudas, Ph.D., showcases how BPGbio, Inc. is drugging the undruggable @ 7th Annual Targeted Protein Degradation (#TPD) and Induced Proximity Summit. The presentation titled "A Novel & Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin Conjugating Enzyme (#E2) Family” occurred today, the first day of the conference, October 28th. BPGbio, Inc. is at the forefront of advancing TPD by designing several CRBN-independent, orally available degraders with nanomolar potency and robust degradation profiles. These developments demonstrate the potential for E2-based #therapeutics in both #oncology and #neurology. BPGbio, Inc.’s E2-based lead molecules are being developed for a range of protein targets linked to various cancers, particularly where CRBN dysfunction may lead to acquired resistance against CRBN / E3-based degraders. The BPGbio, Inc. Protein Homeostasis program also includes E2-based molecular glue leads for Huntingtin homeostasis, with potential extension beyond #Huntington’s Disease to other neurodegenerative or Poly(Q) disorders. For more information on our TPD program, please visit: https://lnkd.in/ghG8APdR #AI #drugdiscovery #proteinhomeostasis #tpdsummit #NAiInterrogativeBiology #Boston #conference #proteindegradation #cancer

🎙 BPGbio, Inc. CEO Niven R Narain, Ph.D. to Present at Google’s Inaugural Cancer AI Symposium 🎙 BPGbio, Inc., a leading biology-first, AI-powered, clinical stage #biopharma focused on mitochondrial biology and protein homeostasis, today announced its participation in the inaugural Google Cancer AI Symposium, in #Boston. BPGbio, Inc. President and CEO Niven R Narain, Ph.D., will deliver a presentation on “Making AI for Discovery Real - Prioritizing Biology before Tech,” on October 30 at 2:45 pm. During the presentation, Dr. Narain will also provide updates on BPGbio, Inc.’s robust portfolio of therapeutic candidates, many of which are in late-stage #clinicaltrials. These candidates have been identified/guided using the company’s proprietary AI-powered #NAiInterrogativeBiology ® Platform, which facilitates target discovery, #biomarker identification, and #drugdevelopment through all stages—from preclinical to late-stage development. The NAi Platform is currently advancing key #partnerships with pharmaceutical companies, academic institutions, and government organizations on various disease indications. BPGbio, Inc.’s therapeutic #pipeline includes candidates for #glioblastoma (orphan drug), #pancreaticcancer (orphan drug), #primaryCoQ10deficiency (rare pediatric disease designation), #epidermolysisbullosa (orphan drug), squamous cell carcinoma (orphan drug), #sarcopenia, solid and liquid tumors, #Huntington’s disease, and #Parkinson’s disease. ➡ Full Release: https://lnkd.in/gJJp-5Nd #AI #GoogleAI #cancer #presentations #biology #drugdiscovery

🎗 It’s #EBAwarenessWeek! Join BPGbio, Inc. and our partner debra of America in raising awareness about #EpidermolysisBullosa. 🎗 #EBAwarenessWeek is October 25-31! #EpidermolysisBullosa is a debilitating group of rare disorders caused by a mutation in one of 18 genes. Individuals with EB face the lifelong challenge of extremely fragile skin that blisters and tears from minor friction. Thousands are living with #EpidermolysisBullosa, a painful and often fatal disorder affecting about 1 in 20,000 births in the U.S. Approximately 200 children are born with #EpidermolysisBullosa every year in the United States. Join BPGbio, Inc. and debra of America for #EBAwarenessWeek (October 25-31) to spread awareness. Learn more about EB and take action at debra.org/ebweek #EBweek #WeFightEB BPGbio, Inc. has partnered with debra of America to support and advocate on behalf of patients and families affected by EB. debra of America is a non-profit organization that provides comprehensive support to those with epidermolysis bullosa (EB). It is the only national organization in the United States to offer free programs and services to affected individuals and their caregivers and fund research for an EB cure and treatment. By joining forces, we hope to galvanize the disease community and advance treatment research further. BPGbio, Inc.’s Epidermolysis Bullosa drug candidate (BPM31510) received #FDA Orphan-Drug Designation in May 2018. To learn about our support & the clinical trial BPGbio, Inc. is conducting related to EB, please visit: https://lnkd.in/gjY5ZEzU Stay tuned for some exciting news from BPGbio, Inc. concerning EB next week! #awareness #clinicaltrials #support #drugdiscovery #NAiInterrogativeBiology #ai #biopharma